FDA OKs Cartridge-Based Companion Diagnostic Test for Colorectal Cancer
The test provides fully automated, sample-to-result testing to identify patients eligible for immunotherapy treatment.
The test provides fully automated, sample-to-result testing to identify patients eligible for immunotherapy treatment.
Two new American Cancer Society studies reveal significant increases in colorectal cancer...
Researchers have discovered how cellular stress and inflammation drive pancreatic cancer progression via the STAT3-ITGB3 pathway.
Personalis has expanded and extended its partnership with Tempus AI to include colorectal cancer in their NeXT Personal MRD test.
Read MoreClearNote Health has received UKCA marking for its Avantect Pancreatic Cancer Test, enabling commercial availability in the UK.
Read MoreVibrant Wellness has enhanced its Gut Zoomer microbiome panel with expanded microbial and metabolite testing.
Read MoreA new prospective study in BMC Cancer shows that the blood-based multi-omics test SeekInClarity accurately predicts treatment outcomes.
Read MoreLunit has partnered with Microsoft to co-develop scalable, AI-powered healthcare solutions that enhance cancer detection.
Read MoreAMP has published consensus best practice recommendations to standardize HRD testing in clinical laboratories.
Read MoreResearchers have developed genomic biomarkers to predict cancer patients’ resistance to chemotherapy, enabling more personalized treatment.
Read MoreLucid Diagnostics and Hoag have launched a comprehensive esophageal precancer screening program using the non-endoscopic EsoGuard DNA test.
Read MoreCAP has updated 23 cancer protocols to align with the latest standards from AJCC and WHO, enhancing diagnostic precision and patient care.
Read MoreResearchers have developed an AI blood test called Fragle to accurately and affordably track cancer treatment response and detect relapse.
Read MoreClearNote Health and University Hospital Southampton have launched the SAFE-D study to evaluate the Avantect Pancreatic Cancer Test.
Read MoreEmerging liquid biopsy techniques enable sensitive, routine monitoring of ESR1 mutations in metastatic HR+ breast cancer.
Read MoreQuest Diagnostics is partnering with MD Anderson Cancer Center to develop a lab-based blood test for cancer that uses protein biomarkers.
Read MoreEchosens and Boehringer Ingelheim have expanded their partnership to improve early detection, diagnosis, and care access for MASH.
Read MoreFlorida Cancer Specialists & Research Institute now offers liquid biopsy, a minimally invasive blood test that enhances cancer diagnosis.
Read More